Liquid biopsy and minimal residual disease — latest advances and implications for cure

By K. Pantel, C. Alix‐Panabières. Nature Reviews Clinical Oncology, 2019

938 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/899e3bf6ee9574e264158268f114e4618c027d82

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. C. Alix‐Panabières
2. K. Pantel
3. J. Reis-Filho

In Molecular Biology

1. C. Alix‐Panabières
2. K. Pantel
3. J. Reis-Filho
4. N. Turner
5. N. Normanno

In Oncology

1. C. Alix‐Panabières
2. K. Pantel
3. J. Reis-Filho

Citations in the corpus

• Liquid Biopsy: From Discovery to Clinical Application. (2021, methodology): “CTC assays start with an enrichment step that increases the concentration of CTCs by several log units and enables an easier detection of single tumor cells (13).”
• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022, methodology): “99 MRD may be detected only by molecular techniques such as PCR or sequencing or CTC analysis, but is not detectable by conventional tests such as current blood-based protein tumour markers or imaging.”